GRONINGEN and OSS, The Netherlands, May 25 /PRNewswire/ -- Kiadis BV and NV Organon announced today that both companies have entered into an evaluation agreement centered around the use of Kiadis' core on-line screening technology, the BioSelact(TM), for the Reproductive Medicine discovery program at Organon.
Under the terms of the collaboration, Organon will supply Kiadis with a proprietary target. Financial details of the collaboration are not disclosed. Kiadis will deliver Organon with novel active compounds against the target utilizing its BioSelact(TM) technology. Organon is particularly interested in the ability of Kiadis' BioSelact(TM) technology to efficiently characterize bioactive compounds present in complex chemical mixtures.
Ton Rijnders, Vice President Research Oss at Organon, said: "Organon has selected the BioSelact(TM) technology because it may accelerate the discovery programs by rapid on-line confirmation of new novel active compounds. This is a great opportunity for Organon to evaluate the potential of the Kiadis technology to identify new leads."
Manja Bouman CEO of Kiadis, commented: "We are very pleased to start this project together with Organon. We are excited and encouraged by the confidence that Organon has shown by entering into this evaluation of BioSelact(TM). This collaboration can be seen as a further validation of the successful commercialization strategy of Kiadis and value of Kiadis' technology."
Kiadis has developed the unique and proprietary BioSelact(TM) platform technology, allowing for a revolutionary drug discovery approach which greatly enhances lead discovery and optimization programs. The BioSelact(TM) platform allows the highly efficient screening of every Compound source of synthetic or natural origin on virtually all pharmaceutical target classes. Kiadis has successfully applied its technology to pharmaceutical and nutraceutical discovery programs.
Organon - with shared head offices in Roseland, NJ, USA and Oss, The Netherlands - creates, manufactures and markets prescription medicines that improve the health and quality of human life. Through a combination of independent growth and business partnerships, Organon strives to remain or become one of the leading pharmaceutical companies in each of its core therapeutic fields: reproductive medicine, psychiatry and anesthesia.
Organon products are sold in over 100 countries, of which more than 60 have an Organon subsidiary. Organon is the human health care business unit of Akzo Nobel.
CONTACT: Kiadis BV, Manja Bouman, CEO, Tel: +31-50-5474270,firstname.lastname@example.org. NV Organon, Monique Mols, AssociateDirector Media Relations, Tel. +31-412-665440,email@example.com